Filling the gap between excellence in basic cancer research and unmet needs in targeted cancer therapies.
With proven success and a pipeline of innovative early stage small molecule oncology programs, backed up with data-rich packages, CTx is an ideal partner for growth-focused pharmaceutical and biotechnology companies who are looking for assets to take to the next stage.
Partnering with CTx comes with a number of commercial upsides including
Working with an organisation with stable funding, resources and technology
Access to expertise in translation of novel biology
Ability to submit own targets
Competitive and transparent revenue sharing arrangements
A hand-built project team with the necessary skills and a project leader that knows drug development
Low risk commercialisation
Beneficial share in our IP Pool
Potential access to Australian R&D Tax Incentive Program for firms that partner for innovation.
For commercial in confidence discussions, contact Brett Carter, CEO, on +61 (3) 6388 7831 or email firstname.lastname@example.org.